Skip to main content
Premium Trial:

Request an Annual Quote

China Med Tech, Gaoxin Da An Partner on MDx Marketing Deal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – China Medical Technologies said today that its wholly owned subsidiary Beijing GP Medical Technologies and Gaoxin Da An Healthcare Investments are collaborating to bring molecular diagnostic technologies to the Chinese market.

Under the deal, GP Medical and Da An Health will co-market and promote GP Medical's molecular diagnostic products to Da An Health's customer base of hospitals. The two companies will also jointly develop new MDx products targeted to Da An Health's hospital customers.

Financial and other terms of the deal were not disclosed.

Based in Beijing, China Medical Technologies develops diagnostics. Its molecular diagnostic products include those using FISH and surface plasmon resonance technologies.

Da An Health provides clinical diagnostic testing services and has eight clinical testing centers serving thousands of hospitals in China.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.